Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Erlotinib in Advanced Breast Cancer
NCT00030537Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Change in Epidermal Growth Factor Receptor Phosphorylation. Started Nov 2001; status: completed.
02
Drugs
erlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00030537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030537.